Recently, CD19/CD22 CAR-T cell therapy following ASCT showed a striking efficacy and manageable toxicity in a prospective study of aggressive B-cell lymphoma, including seven patients with tFL. This evidence concerns the gene CD22 and B-cell non-Hodgkin lymphoma.